Icatibant Universal Farma

Icatibant, the active ingredient in Icatibant Universal Farma, is a bradykinin B2 receptor antagonist presented as a sterile subcutaneous solution for subcutaneous administration. It is used to treat acute attacks of hereditary angioedema caused by C1‑inhibitor deficiency, providing rapid relief of swelling in the skin, gastrointestinal tract, and airway, and associated discomfort in affected patients.

GNH USA supplies Icatibant Universal Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable cold‑chain logistics and regulatory support.

Icatibant is a bradykinin B2 receptor antagonist indicated for hereditary angioedema.

- Acute hereditary angioedema attacks (C1‑inhibitor deficiency): rapid reduction of swelling and restoration of normal airway patency. - Hereditary angioedema type I and II episodes: alleviates cutaneous and abdominal edema to improve patient comfort. - Trauma‑ or procedure‑triggered hereditary angioedema attacks: limits edema severity and shortens episode duration.

Icatibant may cause a range of adverse reactions following subcutaneous injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin irritation. - Nausea: transient gastrointestinal upset. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or bronchospasm. - Anaphylaxis: rapid onset of severe allergic response requiring emergency care. - Severe hypotension: marked drop in blood pressure, potentially leading to dizziness or syncope.

Before using Icatibant, clinicians should consider several safety measures.

- Assess hypersensitivity: avoid in patients with known allergy to icatibant or its excipients. - Monitor cardiovascular status: watch for signs of hypotension, especially in patients with pre‑existing low blood pressure. - Use caution in renal or hepatic impairment: adjust monitoring as these conditions may affect drug clearance. - Pregnancy and lactation: safety has not been established; weigh potential benefits against unknown risks. - Concomitant bradykinin‑enhancing drugs: evaluate risk of additive effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Icatibant can interact with other medicines that influence the bradykinin pathway or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and heighten risk of angioedema. - Angiotensin receptor blockers (ARBs): similar potential to augment bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely): - DPP‑4 inhibitors: theoretical increase in bradykinin activity; monitor for enhanced edema. - Diuretics: may potentiate hypotensive effects; observe blood pressure after administration.